Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Acq. announced
Appointed director
BIOMARIN PHARMACEUTICAL INC (BMRN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 144 Form 144 - Report of proposed sale of securities:
08/09/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 144 Form 144 - Report of proposed sale of securities:
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 8-K Quarterly results
05/11/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 144 Form 144 - Report of proposed sale of securities:
04/28/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/26/2023 8-K Quarterly results
04/06/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 144 Form 144 - Report of proposed sale of securities:
03/13/2023 144 Form 144 - Report of proposed sale of securities:
03/10/2023 144 Form 144 - Report of proposed sale of securities:
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 8-K Quarterly results
Docs: "BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business •VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 Billion"
02/14/2023 SC 13G/A DODGE & COX reports a 7.7% stake in BioMarin Pharmaceutical Inc.
02/13/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/09/2023 SC 13G/A PRIMECAP MANAGEMENT CO reports a 9.5% stake in BioMarin Pharmaceutical Inc.
02/03/2023 SC 13G/A BlackRock Inc. reports a 8.2% stake in BIOMARIN PHARMACEUTICAL INC
01/11/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Relevant Slides from BioMarin Pharmaceutical Inc. J.P. Morgan 2023 Presentation",
"Relevant Slides from BioMarin Pharmaceutical Inc. J.P. Morgan 2023 Presentation"
12/21/2022 8-K Quarterly results
10/28/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/26/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
09/12/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
Docs: "BioMarin Announces Record Revenues in Second Quarter 2022&#59; Increases Full-year 2022 Top and Bottom-line Guidance •VOXZOGO™ $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter&#59; Total Revenues Grew 13% Year-Over-Year, Excluding Kuvan"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy